Senores Pharmaceuticals Ltd.
Fundamentals
- Market cap
- ₹5,840 cr
- P/E
- 50.62×
- ROE
- 7.45%
- Debt / equity
- 0.39
- 52-week range
- 535.85 — 1355.70
Analysis — the numbers vs the call
- Senores Q1 beats on regulated markets; branded generics target cut a credibility gap
Revenue and profit surged, but management slashed domestic branded sales goals by ~40% without explaining why.
The timeline — 6 notes on Senores Pharmaceuticals Ltd.
July 2026
- 27 Jul 26 · 6:30 PM IST Brief Brief · Earnings · Mid cap
Senores Pharma targets 50-60% PAT growth after Q1 beat
Revenue rose 36% to ₹180 cr, PAT up 56% to ₹31 cr. Management guided for full-year PAT growth of 50-60% and plans to commercialize 35 ANDAs over 18-20 months.
- 27 Jul 26 · 5:35 PM IST Brief Brief · Mid cap
Senores delays Atlanta plant, redirects ₹65 cr of IPO funds
The sterile injectables facility at Atlanta won't be ready until Q4 FY28; the company now plans to use freed-up cash for ANDA buys and existing site expansions.
- 27 Jul 26 · 3:49 PM IST Brief Brief · Earnings · Mid cap
Senores Q1 revenue jumps 36% to ₹180 cr, profit up 56%
Regulated markets lead with 42% growth as ANDA portfolio expands to 58 products; EBITDA surges 87% to ₹54 crore.
- 27 Jul 26 · 3:42 PM IST Brief Brief · Earnings · Mid cap
Senores Q1 profit rises 56% on regulated markets growth
Revenue up 36% to ₹180.2 cr, EBITDA surges 87%. Results in line with guided trajectory.
- 27 Jul 26 · 3:35 PM IST Brief Brief · Earnings · Mid cap
Senores' Q1: Revenue up 36%, profit up 56% — in line with guidance
Strong growth but priced in. EBITDA margin expanded to nearly 30%. Anjali Shah appointed as senior management.
- 27 Jul 26 · 3:25 PM IST Brief Brief · Earnings · Mid cap
Senores Q1 profit surges 44% on regulated markets growth
Revenue climbs 36% to ₹180 crore, but the numbers were well telegraphed in guidance.